ArticlePharmaceutics2022
Clinical Pharmacokinetic Assessment of Kratom (
Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 62 citations in OpenAlex.
- Human Mitragynine and 7-Hydroxymitragynine Pharmacokinetics after Single and Multiple Daily Doses of Oral Encapsulated Dried Kratom Leaf Powder.Molecules (Basel, Switzerland) · 2024Trial
- Simultaneous quantification of seventeen kratom alkaloids and metabolites in human plasma and its application to clinical pharmacokinetic sample analysis.Pharmaceutical biology · 2026Article
- Mitragynine and 7-hydroxy-mitragyine plasma pharmacokinetics in humans after single and 15 multiple oral kratom extract doses.Journal of analytical toxicology · 2026Article
- Pharmacokinetic Evaluation of a Cinnamon Product on CYP2A6 Substrate Drugs: Application of a Novel Tool Involving the Nicotine Metabolite Ratio.Clinical pharmacology and therapeutics · 2026Article
- Elevated 7-Hydroxymitragynine Levels Found in Products Misbranded as Kratom.Journal of AOAC International · 2026Article
- Evaluation of the unregulated online kratom market in two east-central European countries: test purchase and analysis of potential toxicological consequences.Harm reduction journal · 2025Article
- Clinically characterizing adults who use kava or kratom: Substance use disorder assessment challenges for increasingly popular botanical products.Drug and alcohol dependence reports · 2025Article
- Evaluating the drug interactions in kratom usage: clinical application.Expert opinion on drug metabolism & toxicology · 2025Review
- Inhibitory effects of Kratom constituents, mitragynine and 7-hydroxymitragynine, on 4-methylumbelliferone glucuronidation by human UDP-glucuronosyltransferases.Toxicology reports · 2025Article
- An exploratory study of the safety profile and neurocognitive function after single doses of mitragynine in humans.Psychopharmacology · 2025Article
- In Vitro and In Vivo Pharmacokinetic Characterization of 7-Hydroxymitragynine, an Active Metabolite of Mitragynine, in Sprague-Dawley Rats.European journal of drug metabolism and pharmacokinetics · 2025Article
- Quantification of 11 kratom alkaloids including mitragynine and its main metabolites in human plasma using LC-MS/MS.Analytical and bioanalytical chemistry · 2025Article
- Multiple-Dose Pharmacokinetics and Safety of Mitragynine, the Major Alkaloid of Kratom, in Rats.ACS pharmacology & translational science · 2024Article
- Kratom addiction per DSM-5 SUD criteria, and kratom physical dependence: Insights from dosing amount versus frequency.Drug and alcohol dependence · 2024Article
- Effects of Itraconazole on Pharmacokinetics of Mitragynine and 7-Hydroxymitragynine in Healthy Volunteers.ACS pharmacology & translational science · 2024Article
- Pharmacokinetic Interaction of Kratom and Cannabidiol in Male Rats.Pharmaceutics · 2024Article
- Effects of kratom on driving: Results from a cross-sectional survey, ecological momentary assessment, and pilot simulated driving Study.Traffic injury prevention · 2024Article
- Kratom safety and toxicology in the public health context: research needs to better inform regulation.Frontiers in pharmacology · 2024Review
- An in vitro evaluation of kratom (Mitragyna speciosa) on the catalytic activity of carboxylesterase 1 (CES1).Chemico-biological interactions · 2023Article
- Translating Kratom-Drug Interactions: From Bedside to Bench and Back.Drug metabolism and disposition: the biological fate of chemicals · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
Increasing use of the botanical kratom to self-manage opioid withdrawal and pain has led to increased kratom-linked overdose deaths. Despite these serious safety concerns, rigorous fundamental pharmacokinetic knowledge of kratom in humans remains lacking. We assessed the pharmacokinetics of a single low dose (2 g) of a well-characterized kratom product administered orally to six healthy participants. Median concentration-time profiles for the kratom alkaloids examined were best described by a two-compartment model with central elimination. Pronounced pharmacokinetic differences between alkaloids with the 3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.